KIT and acute myeloid leukemia: In preclinical models, crenolanib produced sustained FLT3 inhibition, suppressed downstream STAT5 signaling, and induced strong cytotoxic effects in both FLT3-ITD and FLT3-TKD AML cells, while sparing c-KIT at therapeutically relevant concentrations [57].